SCHEDULE: Aberdeen Group Reports Zero Ownership in Corbus Pharma

Aberdeen Group plc and abrdn Inc. have filed a Schedule 13G amendment indicating they no longer beneficially own any shares of Corbus Pharmaceuticals Holdings, Inc.

Summary

• Aberdeen Group plc and abrdn Inc. have filed an amendment to their Schedule 13G filing.
• The filing indicates that both entities now beneficially own 0 shares of Corbus Pharmaceuticals Holdings, Inc. common stock.
• This represents 0% of the class of securities.
• The previous filing date for this event was September 16, 2026.
• Aberdeen Group plc is organized in the United Kingdom, and abrdn Inc. is organized in the United States.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing, primarily due to the reporting of zero beneficial ownership, indicating a divestment or lack of current investment.

Negatives

• Aberdeen Group plc and abrdn Inc. no longer hold any beneficial ownership of Corbus Pharmaceuticals Holdings, Inc. common stock.
• This indicates a complete divestment or lack of investment in the company by these entities.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Management Comments

• Aberdeen Group plc no longer beneficially owns on behalf of our underlying clients any of the outstanding shares of the security class being reported on this Schedule 13G.
• abrdn Inc. no longer beneficially owns on behalf of our underlying clients any of the outstanding shares of the security class being reported on this Schedule 13G.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing typically indicates a passive investment stake. The reporting of zero ownership by significant entities like Aberdeen Group plc and abrdn Inc. suggests a complete exit from their investment in Corbus Pharmaceuticals Holdings, Inc., which could be due to strategic shifts or a reassessment of the company's prospects.

Stakeholder Impact

• Shareholders may note the exit of significant institutional investors, which could be interpreted in various ways depending on market sentiment and the reasons for the divestment.

Key Dates

Keywords

Schedule 13G, Ownership, Beneficial Ownership, Divestment, Securities